鉄剤静脈注射の世界市場レポート 2025年

鉄剤静脈注射の市場規模は今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.2％で、58億6,000万米ドルに成長します。予測期間中の成長は、政府の支援策、静脈内投与（IV）鉄剤分野における研究開発の進行、IV鉄剤治療に対する需要の増加、研究開発活動の活発化、薬剤投与と製剤の改善などに起因すると考えられます。予測期間中に予想される主な動向としては、先進的な静注鉄剤治療の出現、医薬品開発の大幅な進展、より利便性の高い静注鉄剤治療へのシフト、戦略的提携、パートナーシップ、買収、新規ドラッグデリバリーシステムの革新などが挙げられます。

慢性腎臓病（CKD）の罹患率の増加は、鉄剤静脈注射市場の大幅な成長を牽引すると予想されます。CKDは、腎機能が徐々に低下し、血液から老廃物や余分な水分をろ過する機能が損なわれることを特徴とする進行性の疾患です。この増加傾向は、腎臓障害の主な原因である糖尿病と高血圧の有病率の増加に大きく起因しています。鉄剤静脈注射は、鉄レベルを回復させ、ヘモグロビン濃度を改善し、体内の酸素供給を強化することによって、CKDに関連した貧血を管理する上で重要な役割を果たします。これらの利点により、赤血球造血刺激因子製剤への依存度が低下し、患者の転帰が改善されます。例えば、2024年6月、オーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、CKD関連の死亡率が2021年に4.2％、2022年に6.2％増加したと報告しました。2022年だけでも、オーストラリアではCKDによる死亡が約2万2,000人に上り、死亡者全体の11％を占めています。その結果、CKDの負担の増大が、静脈内鉄療法に対する需要を加速させています。

鉄剤静脈注射市場の新興国企業は、安全性、有効性、患者体験を向上させるため、先進的な静脈内鉄補充療法の開発を優先しています。静脈内鉄補給療法は、鉄を直接血流に送り込むもので、特に経口鉄サプリメントに耐えられない、あるいは吸収できない患者において、鉄欠乏症や貧血の効果的な治療法となります。例えば、2023年6月、日本の第一三共株式会社は、米国食品医薬品局（FDA）から、ニューヨーク心臓協会心不全クラスⅡ/Ⅲの成人における鉄欠乏症の治療薬として、インジェクトファー（カルボキシマルトース鉄注射剤）が承認されたと発表しました。この承認は、運動能力を向上させ、主要な患者集団における鉄欠乏に対処するためのInjectaferの使用を支持するものです。迅速な鉄補給で知られるインジェクターファーは、経口療法に代わる貴重な選択肢であり、治療のアドヒアランスとアウトカムを向上させます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界鉄剤静脈注射PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の鉄剤静脈注射市場：成長率分析
• 世界の鉄剤静脈注射市場の実績：規模と成長, 2019-2024
• 世界の鉄剤静脈注射市場の予測：規模と成長, 2024-2029, 2034F
• 世界鉄剤静脈注射総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の鉄剤静脈注射市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄デキストラン
• 鉄スクロース
• カルボキシマルトース第二鉄
• その他の製品タイプ
• 世界の鉄剤静脈注射市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性腎臓病
• 炎症性腸疾患
• がん
• その他の病気
• 世界の鉄剤静脈注射市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の鉄剤静脈注射市場鉄デキストランの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子量鉄デキストラン
• 高分子量鉄デキストラン
• 世界の鉄剤静脈注射市場鉄スクロースのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準鉄ショ糖注射液
• 鉄スクロース複合体
• 世界の鉄剤静脈注射市場、タイプ別カルボキシマルトース第二鉄のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回投与のカルボキシマルトース第二鉄
• 多回投与カルボキシマルトース鉄
• 世界の鉄剤静脈注射市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェルモキシトール
• フェリックデリソマルトース
• グルコン酸第二鉄ナトリウム

第7章 地域別・国別分析

• 世界の鉄剤静脈注射市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の鉄剤静脈注射市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 鉄剤静脈注射市場：競合情勢
• 鉄剤静脈注射市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• CSL Limited
• Sandoz Group AG.
• Daiichi Sankyo Company Ltd.
• Sun Pharmaceutical Industries Ltd.
• Galenica Ltd.
• Dr.Reddy's Laboratories
• Hikma Pharmaceuticals plc
• Zydus Lifesciences Limited
• Biocon Limited
• Kissei Pharmaceutical Co. Ltd.
• American Regent Inc.
• Akebia Therapeutics Inc.
• Rockwell Medical Inc.
• Pharmacosmos A/S
• Shield Therapeutics plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 鉄剤静脈注射市場2029：新たな機会を提供する国
• 鉄剤静脈注射市場2029：新たな機会を提供するセグメント
• 鉄剤静脈注射市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate or do not respond well to oral iron supplements. These drugs quickly elevate iron levels, support hemoglobin production, and enhance oxygen transport in the body, helping to relieve symptoms such as fatigue and weakness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types of intravenous iron drugs include iron dextran, iron sucrose, ferric carboxymaltose, and other formulations. Iron dextran is an injectable iron therapy used for rapid iron replenishment in patients with severe deficiencies where oral iron is ineffective or poorly tolerated. These drugs are used to treat various conditions, including chronic kidney disease, inflammatory bowel disease, cancer, and other disorders. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intravenous iron drugs market research report is one of a series of new reports from The Business Research Company that provides intravenous iron drugs market statistics, including the intravenous iron drugs global market size, regional shares, competitors with the intravenous iron drugs market share, detailed intravenous iron drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the intravenous iron drugs. This intravenous iron drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.44 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth during the historic period can be attributed to the increasing prevalence of iron deficiency anemia, a rise in chronic diseases, growing healthcare expenditure, an aging population, and the rising incidence of target illnesses requiring intravenous iron therapy.

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $5.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth during the forecast period can be attributed to supportive government initiatives, ongoing research and development in the field of intravenous (IV) iron drugs, increasing demand for IV iron therapies, a rising number of R&D activities, and improvements in drug administration and formulation. Key trends expected in the forecast period include the emergence of advanced intravenous iron therapies, significant advancements in drug development, a shift toward more convenient IV iron treatment options, strategic collaborations, partnerships, and acquisitions, as well as innovations in novel drug delivery systems.

The growing incidence of chronic kidney disease (CKD) is expected to drive significant growth in the intravenous iron drugs market. CKD is a progressive condition characterized by the gradual decline of kidney function, impairing the body's ability to filter waste and excess fluids from the blood. This rising trend is largely attributed to the increasing prevalence of diabetes and hypertension two major contributors to kidney damage. Intravenous iron drugs play a crucial role in managing CKD-related anemia by restoring iron levels, improving hemoglobin concentrations, and enhancing oxygen delivery in the body. These benefits reduce reliance on erythropoiesis-stimulating agents and support better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare reported that CKD-related mortality increased by 4.2% in 2021 and by 6.2% in 2022. In 2022 alone, CKD accounted for approximately 22,000 deaths in Australia, representing 11% of total fatalities. As a result, the growing burden of CKD is accelerating the demand for intravenous iron therapies.

Leading players in the intravenous iron drugs market are prioritizing the development of advanced intravenous (IV) iron replacement therapies to enhance safety, efficacy, and patient experiences. IV iron replacement therapy involves delivering iron directly into the bloodstream, making it an effective treatment for iron deficiency and anemia, particularly in patients who are unable to tolerate or absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited a Japan-based pharmaceutical innovator announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adults with New York Heart Association class II/III heart failure. This approval supports the use of Injectafer to improve exercise capacity and addresses iron deficiency in a key patient population. Known for its rapid iron repletion capabilities, Injectafer offers a valuable alternative to oral therapies, enhancing treatment adherence and outcomes.

In August 2022, CSL Limited, an Australia-based biotechnology company known for its focus on plasma therapies and specialty pharmaceuticals, acquired Vifor Pharma for an undisclosed sum. This strategic acquisition enhances CSL's capabilities in nephrology and iron deficiency management, significantly strengthening its portfolio in renal and cardiovascular care. Vifor Pharma AG, headquartered in Switzerland, is recognized globally for its expertise in iron deficiency treatments and nephrology-focused pharmaceuticals.

Major players in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy's Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the intravenous iron drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous iron drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intravenous iron drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous Iron Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous iron drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intravenous iron drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous iron drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose; Other Product Types
• 2) By Indication: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Diseases
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Iron Dextran: Low Molecular Weight Iron Dextran; High Molecular Weight Iron Dextran
• 2) By Iron Sucrose: Standard Iron Sucrose Injection; Iron Sucrose Complex
• 3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose; Multiple-Dose Ferric Carboxymaltose
• 4) By Other Product Types: Ferumoxytol; Ferric Derisomaltose; Sodium Ferric Gluconate
• Companies Mentioned: AbbVie Inc.; Sanofi S.A.; Amgen Inc.; Fresenius SE & Co. KGaA; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intravenous Iron Drugs Market Characteristics

3. Intravenous Iron Drugs Market Trends And Strategies

4. Intravenous Iron Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Intravenous Iron Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intravenous Iron Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intravenous Iron Drugs Market Growth Rate Analysis
• 5.4. Global Intravenous Iron Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intravenous Iron Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intravenous Iron Drugs Total Addressable Market (TAM)

6. Intravenous Iron Drugs Market Segmentation

• 6.1. Global Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Product Types
• 6.2. Global Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Diseases
• 6.3. Global Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Iron Dextran, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low Molecular Weight Iron Dextran
• High Molecular Weight Iron Dextran
• 6.5. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Iron Sucrose, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Iron Sucrose Injection
• Iron Sucrose Complex
• 6.6. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Ferric Carboxymaltose, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Ferric Carboxymaltose
• Multiple-Dose Ferric Carboxymaltose
• 6.7. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ferumoxytol
• Ferric Derisomaltose
• Sodium Ferric Gluconate

7. Intravenous Iron Drugs Market Regional And Country Analysis

• 7.1. Global Intravenous Iron Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intravenous Iron Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intravenous Iron Drugs Market

• 8.1. Asia-Pacific Intravenous Iron Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intravenous Iron Drugs Market

• 9.1. China Intravenous Iron Drugs Market Overview
• 9.2. China Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intravenous Iron Drugs Market

• 10.1. India Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intravenous Iron Drugs Market

• 11.1. Japan Intravenous Iron Drugs Market Overview
• 11.2. Japan Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intravenous Iron Drugs Market

• 12.1. Australia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intravenous Iron Drugs Market

• 13.1. Indonesia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intravenous Iron Drugs Market

• 14.1. South Korea Intravenous Iron Drugs Market Overview
• 14.2. South Korea Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intravenous Iron Drugs Market

• 15.1. Western Europe Intravenous Iron Drugs Market Overview
• 15.2. Western Europe Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intravenous Iron Drugs Market

• 16.1. UK Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intravenous Iron Drugs Market

• 17.1. Germany Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intravenous Iron Drugs Market

• 18.1. France Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intravenous Iron Drugs Market

• 19.1. Italy Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intravenous Iron Drugs Market

• 20.1. Spain Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intravenous Iron Drugs Market

• 21.1. Eastern Europe Intravenous Iron Drugs Market Overview
• 21.2. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intravenous Iron Drugs Market

• 22.1. Russia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intravenous Iron Drugs Market

• 23.1. North America Intravenous Iron Drugs Market Overview
• 23.2. North America Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intravenous Iron Drugs Market

• 24.1. USA Intravenous Iron Drugs Market Overview
• 24.2. USA Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intravenous Iron Drugs Market

• 25.1. Canada Intravenous Iron Drugs Market Overview
• 25.2. Canada Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intravenous Iron Drugs Market

• 26.1. South America Intravenous Iron Drugs Market Overview
• 26.2. South America Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intravenous Iron Drugs Market

• 27.1. Brazil Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intravenous Iron Drugs Market

• 28.1. Middle East Intravenous Iron Drugs Market Overview
• 28.2. Middle East Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intravenous Iron Drugs Market

• 29.1. Africa Intravenous Iron Drugs Market Overview
• 29.2. Africa Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intravenous Iron Drugs Market Competitive Landscape And Company Profiles

• 30.1. Intravenous Iron Drugs Market Competitive Landscape
• 30.2. Intravenous Iron Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Intravenous Iron Drugs Market Other Major And Innovative Companies

• 31.1. CSL Limited
• 31.2. Sandoz Group AG.
• 31.3. Daiichi Sankyo Company Ltd.
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Galenica Ltd.
• 31.6. Dr.Reddy's Laboratories
• 31.7. Hikma Pharmaceuticals plc
• 31.8. Zydus Lifesciences Limited
• 31.9. Biocon Limited
• 31.10. Kissei Pharmaceutical Co. Ltd.
• 31.11. American Regent Inc.
• 31.12. Akebia Therapeutics Inc.
• 31.13. Rockwell Medical Inc.
• 31.14. Pharmacosmos A/S
• 31.15. Shield Therapeutics plc

32. Global Intravenous Iron Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous Iron Drugs Market

34. Recent Developments In The Intravenous Iron Drugs Market

35. Intravenous Iron Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Intravenous Iron Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intravenous Iron Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intravenous Iron Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34882_Intravenous_Iron_Drugs_GMR_2025